Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesBariatric & Obesity Managementmeridian GLP-1 pediatric coverage update | OpenPay…
    Ask Trek AI about this page
    CurrentmeridianPolicy MDN.CP.PMN.305

    Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Weight Management Benefit for Pediatric Members

    Customize your policy alerts

    Sign up for meridian Policy MDN.CP.PMN.305 alerts

    Get alerted when Policy MDN.CP.PMN.305 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization requirements for liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound) when requested for chronic weight management in pediatric members through the EPSDT benefit; applies to Meridian Medicaid lines of business.

    Policy Summary
    Payermeridian
    PolicyGlucagon-Like Peptide-1 (GLP-1) Receptor Agonists Weight Management Benefit for Pediatric Members
    Policy CodePolicy MDN.CP.PMN.305
    Change TypeNo material change
    Effective DateMar 1, 2026
    Last ReviewJan 26, 2026
    Next Review Date
    Key ActionProvider must submit documentation (office chart notes, lab results, or other clinical information) supporting that the member has met all approval criteria and request prior authorization through the EPSDT benefit.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3GLP-1 agents covered
    ≥12Min pediatric age
    EPSDTPA route
    5

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Reference citations
    1State precedence note

    Coverage Criteria for Pediatric GLP-1 Receptor Agonists

    Initial Approval Criteria

    Covered when ALL of the following are met (EPSDT route):

    Provider documentation: Provider submits documentation (such as office chart notes, lab results, or other clinical information) supporting that the member has met all approval criteria and the request is processed through the EPSDT prior authorization route.

    Per policy/criteria: documentation must be provided to support medical necessity.

    Benefit exclusion acknowledgement: Provider acknowledges that weight loss is a benefit exclusion and is not a covered benefit, but the request is being considered under the EPSDT benefit pathway.

    Policy states 'Weight loss is a benefit exclusion and is not a covered benefit.' EPSDT requests are handled per criteria.

    Continuation Therapy

    Continued therapy:

    Continuation eligibility: Not eligible for continued therapy for Weight Management Requests processed through the EPSDT benefit as stated in this section.

    Document excerpt indicates 'Not eligible for continued therapy.' Full context of continuation policy not present in this partial document.

    Policy purpose and applicability

    Policy guidance and applicability statements present in excerpt

    Purpose and scope: This clinical policy is a guide to medical necessity to assist coverage decisions and administering benefits; it does not constitute a contract or guarantee of payment.

    Policy explains its role in coverage decisions and limitations.

    Standards and sources: The policy was developed by experienced clinicians based on generally accepted standards of medical practice, peer-reviewed literature, government approvals, evidence-based guidelines, and expert opinion.

    Source describes the evidence and standards used to develop the policy.

    Applicability to coverage documents and state requirements: Coverage decisions and benefit administration are subject to the terms, conditions, exclusions, and limitations of coverage documents and to state and federal requirements; for Medicaid members, state Medicaid coverage provisions take precedence when they conflict with this clinical policy.

    Explicit statement that state Medicaid manual provisions prevail for Medicaid members.

    Coadministration: coadministration with other liraglutide-, semaglutide-, tirzepatide-containing products or with any other GLP-1 receptor agonists is not recommended. Contraindications and boxed warnings that may affect clinical use include a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), prior hypersensitivity to liraglutide, semaglutide, tirzepatide, or any excipients, and a boxed warning for risk of thyroid C-cell tumors.

    The provided excerpt does not list any additional specific clinical exclusions beyond the contraindications and limitations described elsewhere in the policy. Providers should refer to the full clinical policy and coverage documents for any member- or state-specific exclusionary provisions when preparing an authorization request.

    Policy statement: weight loss is a benefit exclusion and is not a covered benefit. However, requests processed through the EPSDT benefit are considered under the policy's specified approval criteria.

    The excerpt does not enumerate conditions explicitly labeled as 'not medically necessary.' The clinical policy is presented as a guide to medical necessity and directs that coverage determinations remain subject to the terms, conditions, exclusions, and limitations of the member's coverage documents and applicable state and federal requirements.

    Product Availability, Formulations, and Dosing

    Product availability / formulationsNDC
    Liraglutide (Saxenda) pre-filled multi-dose pens0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3 mg (6 mg/mL, 3 mL)
    Semaglutide (Wegovy) pre-filled single-dose pens0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
    Tirzepatide (Zepbound) pre-filled single-dose pens and vials2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
    Pediatric age threshold and BMI percentiles
    Pediatric age thresholdAge ≥ 12 years (policy references pediatric patients aged ≥ 12 years)
    BMI obesity cutoff (general)BMI ≥ 95th percentile by age and sex for pediatric patients aged ≥ 12 years; specific 95th-percentile BMI values by half-year age and sex are provided in Appendix D
    Example BMI percentile values (selected ages)At 12 years: male 24.2, female 25.2; at 14 years: male 26.0, female 27.2; at 17.5 years: male 28.6, female 30.0
    Recommended maintenance dosage
    Recommended maintenance dosage (GLP-1 injectable weekly examples)Maintenance dosages listed include 2.4 mg once weekly for semaglutide (Wegovy) and example maintenance dosages of 5 mg, 10 mg, or 15 mg SC once weekly (policy lists these as recommended maintenance dosages).

    Prior Authorization, Documentation, and Provider Responsibilities

    Prior Authorization

    Prior authorization required via EPSDT

    Prior authorization is required through the EPSDT benefit for requests for liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound) when requested for chronic weight management in pediatric members.

    Prior Authorization

    Prior authorization rules for GLP-1 RAs

    The clinical policy establishes prior authorization requirements for GLP-1 receptor agonists used for pediatric weight management; product availability, dosing, and applicable codes are specified elsewhere in the policy and used in authorization decisions.

    • Product availability and dosing examples influence authorization decisions (see product availability and dosing sections).
    • Specific billing or prior authorization code references are maintained elsewhere in the policy and are applied to requests for these agents.

    Clinical Background

    GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) are indicated for use in combination with diet and increased physical activity to reduce and maintain weight loss in adults and in pediatric patients aged 12 years and older for specific agents; clinical use is subject to contraindications, boxed warnings, and dosing escalation as outlined in the full policy.

    Key Definitions and Abbreviations

    EPSDT definition
    DefinitionEPSDT = Early and Periodic Screening, Diagnostic, and Treatment benefit for Medicaid pediatric members
    Policy roleEPSDT is the route through which prior authorization for pediatric weight management requests is processed
    ApplicabilityEPSDT applies to Medicaid pediatric members and may override routine benefit exclusions for weight loss when medically necessary
    BMI definition
    DefinitionBMI = 703 × [weight (lbs) / height (inches)^2]
    Location of formulaFormula and BMI percentile cutoffs are provided in Appendix D of the policy
    Policy Summary
    Payermeridian
    PolicyGlucagon-Like Peptide-1 (GLP-1) Receptor Agonists Weight Management Benefit for Pediatric Members
    Policy CodePolicy MDN.CP.PMN.305
    Change TypeNo material change
    Effective DateMar 1, 2026
    Last ReviewJan 26, 2026
    Next Review Date
    Key ActionProvider must submit documentation (office chart notes, lab results, or other clinical information) supporting that the member has met all approval criteria and request prior authorization through the EPSDT benefit.
    SourceLink
    On This Page
    Coverage Criteria for Pediatric GLP-1 Receptor AgonistsProduct Availability, Formulations, and DosingPrior Authorization, Documentation, and Provider ResponsibilitiesClinical BackgroundKey Definitions and Abbreviations
    Liraglutide (Saxenda) dosing note
    Pediatric dose escalation may take up to 8 weeks; maintenance (maximum) dose for liraglutide is 3 mg SC once daily; reduce to 2.4 mg daily if 3 mg is not tolerated; discontinue if 2.4 mg not tolerated.
    Semaglutide (Wegovy) dosing noteAfter escalation, maintenance dosage may be 1.7 mg or 2.4 mg once weekly (2.4 mg/week recommended); initiation and escalation dosages (0.25–1 mg) are not approved as maintenance.
    Tirzepatide (Zepbound) maintenance referencePolicy lists tirzepatide (Zepbound) maintenance dosing examples (policy notes maintenance dosing for tirzepatide; see dosing tables).
    Note

    Therapeutic alternatives (Appendix B)

    Therapeutic alternatives are listed in Appendix B; the alternatives table provides preferred alternative therapies and notes that listed drugs may require prior authorization per formulary.

    • Appendix B lists preferred alternative therapies and may include dosing examples.
    • Alternatives may not be formulary agents for all lines of business and can require prior authorization.
    Step Therapy

    Step therapy not specified in excerpt

    The provided document excerpt does not specify any explicit step therapy requirements for pediatric GLP-1 RA weight management.

    • No step therapy sequence or mandatory trials are described in the excerpt.
    Documentation Required

    Submit clinical documentation with PA

    Submit supporting clinical documentation with the prior authorization request, such as office chart notes, laboratory results, or other clinical information demonstrating the member meets all approval criteria.

    • Documentation must show that the member meets the EPSDT/approval criteria outlined in the policy.
    • Include relevant clinical data (e.g., BMI percentiles, age, prior treatments) as applicable to the request.
    Documentation Required

    Follow standards of practice and plan rules

    Providers must follow generally accepted standards of medical practice and applicable Health Plan administrative policies; this clinical policy is a guide to medical necessity and coverage is subject to coverage documents and state/federal requirements.

    • Medical record documentation should be consistent with standard clinical practice and plan-level requirements.
    • Coverage is subject to terms, exclusions, and limitations in the member's coverage documents.
    Denial Risk

    Weight-loss exclusion; EPSDT pathway applies

    The policy states that weight loss is a benefit exclusion and is not a covered benefit, but EPSDT weight management requests are handled through the EPSDT prior authorization criteria in this clinical policy.

    • Even though weight loss is generally an exclusion, EPSDT requests may be considered when submitted with required documentation through EPSDT.
    Denial Risk

    State Medicaid provisions may supersede policy

    For Medicaid members, state Medicaid coverage provisions take precedence over this clinical policy; when state provisions conflict with this policy, failure to follow state Medicaid manual requirements may result in denial.

    • Check the applicable state Medicaid manual for coverage provisions that may supersede this policy.
    Use in policy
    BMI percentiles (95th percentile) are used to define obesity thresholds for pediatric members aged ≥ 12 years
    Recommended maintenance dosage (definition entry)
    Example maintenance dosingRecommended maintenance dosage example: 5 mg, 10 mg, or 15 mg SC once weekly
    Document typeProvided in policy dosing examples as a recommended maintenance regimen
    Cross-referenceSee other agent-specific dosing sections for semaglutide and liraglutide maintenance doses